Targeted inhibition of phi class glutathione transferase for reversing herbicide resistance in weeds
This research explores targeting phi class glutathione transferase (MHR-GSTF) to overcome multiple-herbicide resistance in weeds. By inhibiting this enzyme, existing herbicides can regain efficacy, reversing resistance in species like Alopecurus myosuroides and Lolium rigidum.
Overview
This research proposes a novel approach to tackle multiple-herbicide resistance (MHR) in weeds by targeting the phi class glutathione transferase enzyme (MHR-GSTF). MHR-GSTF helps resistant weeds detoxify harmful substances produced during herbicide application, contributing to resistance. By inhibiting this enzyme, we can restore the effectiveness of existing herbicides, providing a sustainable solution to manage resistant weed species such as Alopecurus myosuroides and Lolium rigidum.
Technical specifications
Key features:
- MHR-GSTF plays a critical role in detoxifying cytotoxic hydroperoxides formed due to herbicide action.
- Inhibition of MHR-GSTF reverses resistance by preventing the enzyme from exerting regulatory control over protective flavonoid accumulation in weeds.
- GST-inhibiting pharmacophore compounds have been identified that can inhibit MHR-GSTF activity, restoring herbicide control.
Applications:
- Enables existing graminicides to regain efficacy against MHR weeds.
- Provides a method to design highly specific 3D pharmacophores targeting MHR-GSTF enzymes for screening new inhibitory compounds.
Technology readiness level
The technology is currently at TRL 4, with validation ongoing. The next steps include understanding the structure and function of MHR-GSTF across different species, designing specific pharmacophores, and validating inhibitor interactions through kinetic analysis and biophysical methods. These efforts aim to confirm the inhibitors' effectiveness as herbicide synergists, reversing resistance and restoring control over resistant weed populations.
About Enzyceuticals
EnzyCeuticals is a biotechnology company founded in 2021 as a spin-off from the Agricultural University of Athens. The company specializes in the development and manufacture of innovative, high-quality enzymes and enzyme-based products for the food, health, and cosmetic industries. They utilize their proprietary iEζC platform technology, which integrates omics, bioinformatics, artificial intelligence, synthetic biotechnology, and protein engineering to accelerate enzyme discovery and design. Their offerings include a diverse portfolio of recombinant and native enzymes, proprietary Xenobody protein libraries, and affinity adsorbents, with production maintained under ISO 9001 standards.
These solutions enable customers across various sectors to implement sustainable enzymatic processes. By leveraging their cross-disciplinary expertise, EnzyCeuticals provides novel candidates for applications such as biosensing, bioscavenging, biocatalysis, and drug delivery. The company is recognized as an official member of the Greek startup ecosystem, Elevate Greece, and focuses on developing safe, sustainable, and financially viable enzyme technologies to drive the enzyme bioeconomy. Their work supports both R&D initiatives and industrial-scale requirements, helping partners optimize their operations through advanced biotechnological routes.
Inquire about this partnering listing
Industry applications
delivered to your inbox.